Residency · Residency · Gastroenterology

Alcoholic Liver Disease and Alcohol-Associated Hepatitis

Spectrum of Alcoholic Liver Disease

Progression

Alcoholic liver disease encompasses a broad clinical spectrum ranging from simple steatosis to cirrhosis, with alcohol-associated hepatitis representing a distinct and potentially devastating clinical syndrome that may complicate any stage of this continuum. Understanding the progression of disease is essential for risk stratification, early intervention, and appropriate management.

Steatosis, or fatty liver, is present in more than 90% of individuals who engage in heavy alcohol consumption and represents the earliest and most common histologic manifestation of alcohol-induced liver injury. This stage is typically asymptomatic and fully reversible with sustained abstinence from alcohol. Hepatocyte accumulation of triglycerides occurs primarily in zone 3 of the hepatic acinus and is driven by alcohol-mediated alterations in lipid metabolism, including increased fatty acid synthesis, decreased fatty acid oxidation, and impaired hepatic secretion of very-low-density lipoproteins.

Alcohol-associated steatohepatitis develops in approximately 10 to 35% of heavy drinkers and is characterized by hepatocyte injury accompanied by inflammatory cell infiltration. This stage may be clinically subclinical or may manifest with mild symptoms such as fatigue and hepatomegaly. Histologically, steatohepatitis is distinguished from simple steatosis by the presence of hepatocyte ballooning, Mallory-Denk bodies, neutrophilic inflammation, and early pericellular fibrosis.

Alcohol-associated hepatitis is a clinical syndrome defined by the acute onset of jaundice and hepatic decompensation in the setting of heavy, ongoing alcohol use. This syndrome represents a severe inflammatory insult to the liver and carries a 20 to 40% 90-day mortality in its most severe form. It is critical to recognize that alcohol-associated hepatitis is a clinical diagnosis distinct from the histologic finding of steatohepatitis, though the two frequently coexist.

Cirrhosis develops in 10 to 20% of heavy drinkers over a period of 10 to 20 years of sustained consumption. Many patients present with cirrhosis and superimposed alcohol-associated hepatitis, creating a particularly challenging clinical scenario with compounded morbidity and mortality. Importantly, the progression through these stages is not strictly sequential. Patients may present with alcohol-associated hepatitis without any previously recognized liver disease, and some progress directly from steatosis to cirrhosis without clinically apparent intervening stages.

Risk Factors for Progression

The quantity and duration of alcohol consumption are the most important determinants of disease progression. The thresholds for increased risk are generally considered to be greater than 40 grams per day in women and greater than 60 grams per day in men, with risk escalating substantially after more than 10 years of heavy use. Female sex confers increased susceptibility to alcohol-induced liver injury at lower doses of alcohol consumption. This heightened vulnerability is attributed to several factors, including reduced first-pass metabolism of alcohol due to lower gastric alcohol dehydrogenase activity, a higher proportion of body fat relative to water leading to higher blood alcohol concentrations per unit consumed, and estrogen-mediated potentiation of hepatotoxic mechanisms including enhanced endotoxin-driven Kupffer cell activation.

The convergence of obesity and metabolic syndrome with alcohol use creates a synergistic risk for liver injury that has been increasingly recognized as a distinct clinical entity. The concept of "BAFLD" (both alcohol and fatty liver disease) captures patients in whom metabolic and alcohol-related insults coexist, driving accelerated disease progression. Genetic factors also play an important role. The PNPLA3 rs738409 polymorphism, encoding the I148M variant, is the strongest genetic risk factor for alcoholic liver disease progression and has been associated with increased susceptibility to steatosis, steatohepatitis, fibrosis, and hepatocellular carcinoma. Additional genetic risk loci include TM6SF2, MBOAT7, and HSD17B13, the latter of which appears to confer a protective effect.

Nutritional deficiency is exceedingly common in patients with alcohol use disorder and exacerbates hepatic injury through multiple mechanisms. Deficiencies in folate, thiamine, and zinc are particularly prevalent and contribute to impaired hepatocyte regeneration, oxidative stress, and immune dysfunction. Binge drinking patterns, independent of total alcohol consumption, represent an additional risk factor for the development of acute liver injury. Concomitant viral hepatitis, particularly hepatitis B and hepatitis C, accelerates fibrosis progression synergistically with alcohol, and screening for viral coinfection is mandatory in all patients with suspected alcoholic liver disease.

Pathogenesis

Mechanisms of Liver Injury

The pathogenesis of alcoholic liver disease is multifactorial and involves the interplay of direct hepatotoxicity, oxidative stress, immune activation, and gut-liver axis dysfunction. The primary metabolite of alcohol, acetaldehyde, is directly toxic to hepatocytes through formation of protein and DNA adducts, disruption of mitochondrial function, and induction of immunogenic neoantigen formation. Acetaldehyde-protein adducts stimulate both humoral and cell-mediated immune responses that perpetuate hepatocyte injury even during periods of reduced alcohol consumption.

Chronic alcohol exposure induces the cytochrome P450 2E1 (CYP2E1) enzyme system, which metabolizes ethanol to acetaldehyde while generating reactive oxygen species and promoting lipid peroxidation. The resulting oxidative stress damages hepatocyte membranes, proteins, and DNA, contributing to cell death and inflammation. Concurrently, mitochondrial dysfunction is a hallmark of chronic alcohol exposure, manifesting as impaired fatty acid beta-oxidation that drives the accumulation of intracellular lipid and exacerbates steatosis.

The gut-liver axis plays a central role in the pathogenesis of alcohol-associated hepatitis. Alcohol disrupts intestinal barrier integrity by damaging tight junctions between enterocytes, thereby increasing intestinal permeability. This allows translocation of lipopolysaccharide (endotoxin) and other pathogen-associated molecular patterns from the gut lumen into the portal circulation. LPS activates hepatic Kupffer cells through Toll-like receptor 4, triggering the release of pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6, which orchestrate the inflammatory cascade that characterizes steatohepatitis and alcohol-associated hepatitis.

Neutrophilic infiltration is a histologic hallmark of alcohol-associated hepatitis and distinguishes it from other forms of hepatitis. Neutrophil extracellular traps contribute to tissue damage through the release of proteolytic enzymes and generation of additional oxidative stress. Hepatic stellate cell activation, driven by inflammatory mediators and direct stellate cell injury, leads to collagen deposition in a pattern that is initially perivenular and perisinusoidal, predominantly in zone 3 of the hepatic acinus.

Histologic Features

The histologic features of alcoholic liver disease evolve with disease stage and severity. Steatosis is characterized by macrovesicular fat accumulation, with large lipid droplets displacing the hepatocyte nucleus to the cell periphery. This finding predominates in zone 3 of the hepatic acinus, surrounding the central vein.

Steatohepatitis adds to the steatotic background the hallmark features of hepatocyte ballooning, Mallory-Denk bodies (aggregates of damaged cytokeratin intermediate filaments that appear as eosinophilic, ropey cytoplasmic inclusions), and neutrophilic inflammation with the characteristic pattern of satellitosis, in which neutrophils cluster around injured hepatocytes. Pericellular and perisinusoidal fibrosis in a "chicken wire" pattern is typically present and best visualized on trichrome staining.

In severe alcohol-associated hepatitis, the histologic picture is dominated by extensive neutrophilic infiltration, hepatocyte necrosis, cholestasis with bile plugging of canaliculi, and fibrosis that often reaches bridging or cirrhotic proportions. Additional findings seen in chronic alcohol use include megamitochondria and glycogenated nuclei, which reflect ongoing metabolic disruption.

Alcohol-Associated Hepatitis (AH) -- Clinical Syndrome

Definition (NIAAA Consensus 2016)

The National Institute on Alcohol Abuse and Alcoholism established consensus criteria in 2016 to standardize the diagnosis of alcohol-associated hepatitis. The definition requires the onset of jaundice with a serum bilirubin exceeding 3 mg/dL within 8 weeks, occurring in the context of active heavy alcohol use (greater than 40 grams per day in women, greater than 60 grams per day in men) for at least 6 months, with fewer than 60 days of abstinence before symptom onset. Other causes of liver injury must be excluded, including viral hepatitis, drug-induced liver injury, autoimmune hepatitis, biliary obstruction, and ischemic hepatopathy.

The typical laboratory pattern demonstrates an aspartate aminotransferase exceeding 50 IU/L with an AST to ALT ratio greater than 1.5, and AST values usually remaining below 300 to 400 IU/L. When AST exceeds 500 IU/L, alternative or additional diagnoses should be strongly considered, particularly acetaminophen toxicity and ischemic hepatitis.

Clinical Presentation

The clinical presentation of alcohol-associated hepatitis is characterized by the rapid onset of jaundice, tender hepatomegaly, fever (which may occur even in the absence of infection), and leukocytosis that often exceeds 20,000 cells per microliter with a pronounced left shift. Malnutrition is invariably present and contributes to the morbidity and mortality of the disease.

Signs of hepatic decompensation are common at presentation. Ascites is present in 50 to 60% of patients, hepatic encephalopathy in 15 to 30%, and variceal bleeding may complicate the clinical course. The high prevalence of concomitant infections, occurring in 25 to 50% of patients, necessitates aggressive screening with blood cultures, urinalysis and urine culture, chest radiography, and diagnostic paracentesis in all patients presenting with ascites.

Diagnosis

In the setting of a typical clinical presentation meeting NIAAA criteria, alcohol-associated hepatitis is a clinical diagnosis that does not mandate liver biopsy for confirmation. The laboratory pattern of elevated bilirubin (often exceeding 10 to 20 mg/dL), AST in the range of 100 to 400 IU/L with the characteristic AST-to-ALT ratio greater than 1.5 to 2, elevated INR, low serum albumin, and leukocytosis provides a distinctive biochemical fingerprint.

Liver biopsy remains the gold standard for histologic confirmation and is indicated when the diagnosis is uncertain, when competing etiologies cannot be excluded on clinical grounds, or when enrollment in a clinical trial is being considered. The transjugular approach is preferred given the coagulopathy inherent in these patients, and this approach has the added advantage of permitting simultaneous measurement of the hepatic venous pressure gradient. Histologic features include steatohepatitis with neutrophilic infiltration, hepatocyte ballooning and necrosis, Mallory-Denk bodies, and cholestasis.

Prognostic Scoring

Several prognostic scoring systems have been developed to stratify severity and guide treatment decisions in alcohol-associated hepatitis. The Maddrey Discriminant Function is calculated as 4.6 multiplied by the difference between the patient's prothrombin time and the control prothrombin time, plus the total bilirubin value. A discriminant function of 32 or greater defines severe alcohol-associated hepatitis and is associated with a 28-day mortality of 30 to 50% without treatment.

The Model for End-Stage Liver Disease score is increasingly used over the Maddrey DF due to its continuous nature and broader validation. A MELD score of 20 or greater predicts significant 90-day mortality and identifies patients who should be considered for corticosteroid therapy. The ABIC score incorporates age, bilirubin, INR, and creatinine to stratify patients into low-risk (score less than 6.71), intermediate-risk (6.71 to 9), and high-risk (greater than 9) categories for mortality.

The Lille score is uniquely designed to assess response to corticosteroid therapy at day 7. It incorporates the change in bilirubin between day 0 and day 7 along with other clinical variables. A Lille score greater than 0.45 identifies non-responders, in whom corticosteroids should be discontinued to avoid futile immunosuppression and its attendant infection risk. A Lille score below 0.16 identifies complete responders, while scores between 0.16 and 0.45 indicate partial response. The Glasgow Alcoholic Hepatitis Score incorporates age, white blood cell count, urea, bilirubin, and INR, with a score of 9 or greater indicating severe disease.

<image>A severity assessment and treatment decision algorithm for alcohol-associated hepatitis. Start with "Clinical diagnosis of AH (jaundice + heavy alcohol use + AST:ALT > 1.5)." First step: "Calculate mDF and MELD." Two pathways: (1) "Mild-Moderate AH (mDF <32, MELD <20)": "Supportive care: alcohol cessation, nutritional support (35-40 kcal/kg/day, 1.2-1.5 g protein/kg/day), thiamine/folate/zinc, monitor for complications." (2) "Severe AH (mDF >= 32 or MELD >= 20)": "Rule out infection (blood cultures, UA, CXR, diagnostic paracentesis). If active infection: treat infection first, reassess for steroids when controlled." If no uncontrolled infection: "Prednisolone 40 mg PO daily x 28 days." At Day 7: "Calculate Lille score." If Lille <= 0.45 (responder): "Complete 28-day course; taper optional (not clearly beneficial)." If Lille > 0.45 (non-responder): "Stop prednisolone; consider pentoxifylline discontinuation (no benefit per STOPAH); consider early liver transplant evaluation if appropriate." Bottom pathway for non-responders: "Consider early liver transplant (select patients with first liver decompensation, psychosocial support, low relapse risk) — 6-month rule increasingly abandoned." Include mortality statistics: untreated severe AH 28-day mortality 30-50%, corticosteroid responders 15-20%, non-responders 40-50%. Use red for high-risk, green for responders, yellow for reassessment points.</image>

Treatment of Severe AH

Supportive Care (ALL Patients)

Supportive care measures are the foundation of management for all patients with alcohol-associated hepatitis, regardless of severity. Alcohol cessation is the single most important intervention and dramatically improves both short-term and long-term outcomes. Every clinical encounter should include counseling, motivational interviewing, and referral to addiction medicine services.

Nutritional support is critically important and often underappreciated. Patients should receive a caloric target of 35 to 40 kcal/kg/day and protein intake of 1.2 to 1.5 g/kg/day. The enteral route is strongly preferred, and tube feeding should be initiated if the patient is unable to meet caloric goals through oral intake alone. It must be emphasized that hepatic encephalopathy is not a contraindication to protein provision. Protein restriction is harmful, promotes sarcopenia and muscle catabolism, and paradoxically worsens encephalopathy by increasing ammonia generation from skeletal muscle breakdown.

Thiamine supplementation at 100 to 500 mg intravenously daily is essential to prevent and treat Wernicke encephalopathy, and must be administered before glucose-containing solutions to avoid precipitating this devastating neurologic complication. Deficiencies in folate, zinc, and magnesium should be identified and repleted. Comprehensive infection screening is mandatory before initiating corticosteroid therapy, as infections must be treated before immunosuppression is introduced. Venous thromboembolism prophylaxis should be provided unless contraindicated by severe coagulopathy.

Corticosteroids

Prednisolone 40 mg orally daily for 28 days is the standard treatment for severe alcohol-associated hepatitis. Prednisolone is preferred over prednisone because it does not require hepatic conversion to its active form, an important consideration in patients with significantly impaired liver function. The STOPAH trial, the largest randomized controlled trial in alcohol-associated hepatitis with 1,103 patients, demonstrated that prednisolone reduced 28-day mortality with an odds ratio of 0.72, though this did not reach statistical significance at p = 0.06. However, meta-analyses incorporating multiple trials have consistently demonstrated a clear survival benefit for corticosteroids in severe alcohol-associated hepatitis.

Contraindications to corticosteroid therapy include uncontrolled infection, active gastrointestinal bleeding, hepatorenal syndrome type 1, and multi-organ failure. The Lille score must be calculated at day 7 of therapy. If the score exceeds 0.45, corticosteroids should be discontinued, as continued treatment is futile and increases infection risk without survival benefit. After completion of the 28-day course, some clinicians taper the dose over 2 to 4 weeks, though no clear evidence supports the necessity or benefit of a steroid taper.

Pentoxifylline

Pentoxifylline is no longer recommended for the treatment of alcohol-associated hepatitis. The STOPAH trial definitively demonstrated no benefit on 28-day or 90-day mortality, either as monotherapy or in combination with prednisolone, ending years of debate about its role in this condition.

N-Acetylcysteine (NAC)

The combination of N-acetylcysteine with prednisolone has shown promise as adjunctive therapy. In the randomized controlled trial by Nguyen-Khac and colleagues, the addition of NAC to prednisolone reduced 30-day mortality from 24% to 8% and decreased the incidence of infection and hepatorenal syndrome. However, no difference in 90-day survival was observed. The protocol involves intravenous NAC at 150 mg/kg over 24 hours for 5 days, administered concurrently with prednisolone. Given the favorable safety profile and the reduction in short-term mortality and infection, NAC represents a reasonable adjunctive therapy.

Granulocyte Colony-Stimulating Factor (G-CSF)

Several small randomized controlled trials, primarily conducted in India, have demonstrated a survival benefit with granulocyte colony-stimulating factor therapy in severe alcohol-associated hepatitis. The proposed mechanism involves mobilization of CD34-positive stem cells that promote hepatocyte regeneration and hepatic recovery. Despite these encouraging results, G-CSF is not standard of care in Western guidelines, and larger, multicenter trials are needed before its routine adoption can be recommended.

Liver Transplantation for Severe AH

The traditional requirement of 6 months of documented sobriety before liver transplantation eligibility has been increasingly challenged in the context of severe, steroid-refractory alcohol-associated hepatitis. The concept of early liver transplantation for carefully selected patients with severe alcohol-associated hepatitis who fail corticosteroid therapy has gained acceptance based on landmark clinical trials.

The Franco-Belgian study published by Mathurin and colleagues in 2011 demonstrated a dramatic 6-month survival of 77% in patients who received early transplantation compared with 23% in those who did not. The subsequent ACCELERATE trial confirmed these findings with highly selective patient criteria. Selection criteria for early transplantation typically include first liver decompensation, a favorable psychosocial profile with a supportive family structure, low perceived relapse risk as assessed by addiction medicine specialists, and thorough multidisciplinary evaluation.

Alcohol relapse following liver transplantation for severe alcohol-associated hepatitis occurs in 15 to 25% of patients who return to any drinking and 10 to 15% who return to harmful drinking patterns. Graft loss attributable to recurrent alcoholic liver disease occurs in fewer than 5% of cases. While acceptance of early liver transplantation for alcohol-associated hepatitis is growing, it is not universally adopted and requires a rigorous multidisciplinary selection process at experienced centers.

Medications for Alcohol Use Disorder

Pharmacotherapy (Underutilized in GI/Hepatology Practice)

Pharmacotherapy for alcohol use disorder remains dramatically underutilized in gastroenterology and hepatology practice, despite robust evidence supporting its efficacy and the recognition that sustained abstinence is the most important determinant of long-term outcomes in alcoholic liver disease.

Naltrexone is a mu-opioid receptor antagonist available in oral formulation at 50 mg daily or as a monthly intramuscular injection of 380 mg (Vivitrol). It reduces cravings and the number of heavy drinking days. However, naltrexone must be avoided in patients with acute hepatitis (ALT greater than 3 to 5 times the upper limit of normal) or decompensated cirrhosis due to its hepatotoxic potential.

Acamprosate is an NMDA receptor modulator administered at 666 mg three times daily. It is renally excreted and does not undergo hepatic metabolism, making it safe for use in patients with liver disease. It reduces relapse rates and is considered the first-line pharmacologic agent for alcohol use disorder in patients with hepatic impairment.

Baclofen is a GABA-B receptor agonist and the only medication that has been specifically studied in patients with cirrhosis. The Addolorato trial demonstrated benefit in reducing alcohol consumption and promoting abstinence in cirrhotic patients at doses of 5 to 10 mg three times daily.

Disulfiram is an aldehyde dehydrogenase inhibitor that produces an aversive reaction upon alcohol consumption. It is hepatotoxic and must be avoided in patients with liver disease. Gabapentin is used off-label for alcohol use disorder, reduces heavy drinking days, and has a favorable hepatic safety profile.

Brief Intervention

The SBIRT model (Screening, Brief Intervention, and Referral to Treatment) is an evidence-based approach that has been shown to effectively reduce alcohol consumption in a variety of clinical settings. The AUDIT-C questionnaire serves as a validated screening tool for identifying at-risk drinking patterns and should be incorporated into routine hepatology practice.

<image>A histopathological comparison panel of alcoholic liver disease stages. Four panels with H&E stain views. Panel 1 "Steatosis": macrovesicular fat droplets (large clear vacuoles displacing hepatocyte nucleus to periphery) predominantly in zone 3 (around central vein), labeled anatomy showing central vein and portal triad orientation. Panel 2 "Steatohepatitis": ballooned hepatocytes with pale, swollen cytoplasm, Mallory-Denk bodies (eosinophilic ropey cytoplasmic inclusions labeled with arrows), neutrophilic satellitosis (neutrophils surrounding injured hepatocytes), pericellular "chicken wire" fibrosis highlighted in a trichrome stain inset (blue fibrosis around individual hepatocytes). Panel 3 "Severe AH": extensive hepatocyte necrosis, dense neutrophilic infiltration, cholestasis (bile plugs in canaliculi, shown in yellow-brown), Mallory-Denk bodies, and ductular reaction at the periphery of necrotic areas. Panel 4 "Cirrhosis with AH": regenerative nodules surrounded by thick fibrous septa (trichrome stain showing blue fibrosis), superimposed neutrophilic inflammation and ballooning degeneration within nodules. Label all key features with leader lines. Use realistic H&E stain colors and include small insets of Masson trichrome stain for fibrosis visualization in Panels 2 and 4.</image>

Long-Term Management of ALD

Alcohol Cessation Follow-Up

Long-term follow-up of patients with alcoholic liver disease requires ongoing collaboration with addiction medicine services to support sustained abstinence. Regular screening for alcohol use should employ standardized tools such as the AUDIT questionnaire and objective biomarkers. Phosphatidylethanol (PEth) levels have emerged as the preferred biomarker for detecting recent alcohol use, with a half-life of approximately 4 weeks and superior sensitivity and specificity compared with carbohydrate-deficient transferrin or gamma-glutamyl transferase. Pharmacotherapy for alcohol use disorder should be initiated and maintained as described above.

Cirrhosis Management

Patients with alcoholic liver disease-related cirrhosis require comprehensive management following standard cirrhosis care guidelines, including portal hypertension screening, variceal surveillance with upper endoscopy, hepatocellular carcinoma screening, and management of ascites, hepatic encephalopathy, and other complications. Nutritional optimization is of paramount importance in this population, as sarcopenia is highly prevalent and independently associated with increased morbidity and mortality. Dietitian involvement should be integral to the multidisciplinary care of these patients.

HCC Screening

All patients with alcoholic liver disease-related cirrhosis should undergo hepatocellular carcinoma screening with ultrasound with or without alpha-fetoprotein every 6 months. Alcohol-related hepatocellular carcinoma is often diagnosed at later stages compared with other etiologies, in part due to lower adherence to surveillance protocols in this population, highlighting the importance of systematic screening programs and consistent follow-up.

Key Clinical Pearls

• AST:ALT ratio greater than 1.5 to 2:1 is characteristic of alcoholic liver disease, resulting from alcohol-mediated depletion of pyridoxal 5'-phosphate (the active form of vitamin B6), which is a cofactor for ALT synthesis. AST rarely exceeds 300 to 400 IU/L in alcohol-associated hepatitis alone.
• Maddrey Discriminant Function of 32 or greater or MELD of 20 or greater identifies severe alcohol-associated hepatitis requiring treatment consideration with prednisolone.
• Lille score at day 7 is essential for guiding therapy. A score greater than 0.45 indicates non-response, and prednisolone should be discontinued to avoid futile therapy with ongoing infection risk.
• Pentoxifylline is no longer recommended for alcohol-associated hepatitis, as the STOPAH trial demonstrated no benefit.
• NAC as an adjunct to prednisolone reduces 30-day mortality and infection risk and represents a reasonable addition to therapy.
• Early liver transplant for severe alcohol-associated hepatitis in steroid non-responders is supported by multiple studies but requires rigorous multidisciplinary patient selection.
• Protein restriction in hepatic encephalopathy is harmful. Patients should receive 1.2 to 1.5 g/kg/day of protein.
• Acamprosate and baclofen are safe pharmacotherapy options for alcohol use disorder in patients with liver disease. Naltrexone should be avoided in acute hepatitis or decompensated cirrhosis.

References

1. Crabb DW, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance from the AASLD. Hepatology. 2020;71(1):306-333.
2. Thursz MR, et al. Prednisolone or pentoxifylline for alcoholic hepatitis (STOPAH). N Engl J Med. 2015;372(17):1619-1628.
3. Mathurin P, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1790-1800.
4. Nguyen-Khac E, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1781-1789.
5. Louvet A, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348-1354.

Read this lecture as Markdown